Skip to search boxSkip to navigationSkip to main content

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

  • Evelien L.J. Smits
    ,
  • Cindy Lee
    ,
  • Nicola R. Hardwick
    ,
  • Suzanne E. Brooks
    ,
  • Viggo F.I. Van Tendeloo
    ,
  • Kim H. Orchard
  • University of Antwerp
    ,
  • University Hospital Southampton NHS Foundation Trust
    ,
  • University of Southampton
    ,
  • King's College London
Research Output: Contribution to journal Article Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Immunotherapy is currently under active investigation as an adjuvant therapy to improve the overall survival of patients with acute myeloid leukaemia (AML) by eliminating residual leukaemic cells following standard therapy. The graft-versus-leukaemia effect observed following allogeneic haematopoietic stem cell transplantation has already demonstrated the significant role of immune cells in controlling AML, paving the way to further exploitation of this effect in optimized immunotherapy protocols. In this review, we discuss the current state of cellular immunotherapy as adjuvant therapy for AML, with a particular focus on new strategies and recently published results of preclinical and clinical studies. Therapeutic vaccines that are being tested in AML include whole tumour cells as an autologous source of multiple leukaemia-associated antigens (LAA) and autologous dendritic cells loaded with LAA as effective antigen-presenting cells. Furthermore, adoptive transfer of cytotoxic T cells or natural killer cells is under active investigation. Results from phase I and II trials are promising and support further investigation into the potential of cellular immunotherapeutic strategies to prevent or fight relapse in AML patients.

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 757-769

Journal (Volume, Issue Number)

Cancer Immunology, Immunotherapy (Volume 60, Issue 6)

Publication milestones

  • Published - 01/06/2011

Publication status

Published - 01/06/2011

ISSN

0340-7004

External Publication IDs

  • handle.net: 10547/224580
  • Scopus: 79959709351

Access to documents

Publication metrics